Findings show lower hospitalization risk 31 to 120 days after COVID-19 infection
Risks for Diabetes, CVD Up in Acute, Postacute COVID-19 Phases
However, from 13 to 52 weeks after COVID-19, no increase was seen for diabetes mellitus, cardiovascular disease
Data Elements, Definitions for COVID-19 Complications Detailed
Clinical lexicon presents data elements related to cardiovascular and noncardiovascular complications of COVID-19
COVID-19 Vaccine Does Not Increase CV Event Risk in Those With Existing Disease
Findings show safety of BNT162b2 or CoronaVac vaccines in patients with cardiovascular disease
Preexisting Cardiovascular Conditions Tied to Severe COVID-19 in Children
Risk varies considerably across 26 examined cardiovascular conditions
Previous Myocardial Injury Tied to Worse COVID-19 Outcomes
Significant but weaker associations with selected adverse outcomes seen for preexisting hypertension, diabetes, and ischemic heart disease
Vaccination Cuts Severe COVID-19 Risk in Heart Transplant Patients
COVID-19 vaccination is not associated with heart transplant-specific adverse events
Myocarditis, Pericarditis Risk Highest After Second COVID-19 Vaccine Dose
In large cohort, there were 5.55 excess events per 100,000 vaccinees after BNT162b2 and 18.39 after mRNA-1273
Overall Risk of Myopericarditis Low After COVID-19 Vaccine
Overall incidence of myopericarditis does not differ significantly for those receiving COVID-19 vaccines versus non-COVID-19 vaccines
COVID-19-Associated Acute Myocarditis Reported in 2.4 Per 1,000 Patients
AM occurrence is rare, and outcomes differ based on the presence of COVID-19-associated pneumonia